{
  "abstract": "Optic neuritis is a rare immune-related adverse event of immune checkpoint inhibitor use and may result in poor visual outcomes. We describe an elderly woman with metastatic malignant melanoma treated with nivolumab, a programmed cell death protein 1 immune checkpoint inhibitor. After 2 months, she developed bilateral painless loss of vision due to optic neuritis. Although there is limited evidence, expert opinion favours early corticosteroid use and/or plasma exchange, as recommended for neuromyelitis optica spectrum disorders. Optic neuritis is increasingly recognised as an immune-related adverse event, likely to occur more frequently with greater use of immune checkpoint inhibitors. Its early recognition is important as prompt treatment can improve outcomes.",
  "authors": [
    {
      "affiliations": [
        "Department of Neurology, Southampton General Hospital, Southampton, UK"
      ],
      "name": "Chris Gyan"
    },
    {
      "affiliations": [
        "Neurosciences, Mater Dei Hospital, Msida, Malta, Malta"
      ],
      "name": "Maria Bonello"
    },
    {
      "affiliations": [
        "Department of Neurology, Southampton General Hospital, Southampton, UK"
      ],
      "name": "Ashwin Arnold Pinto"
    }
  ],
  "title": "Immune checkpoint inhibitor-associated bilateral optic neuritis",
  "uid": "9c43e32f-4401-5001-981a-29b8b1059001"
}